🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Editorial board member spotlight: Dr. Kamran Ahmed Kamran Ahmed is an Associate Vice Chair of Research MoffittRadOnc. He is the PI of several multicenter trials in the management of brain metastases and leptomeningeal disease with novel therapeutics and radiation therapy.

Thank you PDBrown ! Team effort led by MoffittRadOnc resident Vaseem Khatri

Congratulations to Moffitt's Peter Johnstone, MD, for being awarded the Amer. Radium Society Gold Medal this year! 🏅 This honor recognizes his outstanding contributions to oncology and exceptional service to the American Radium Society. Congratulations to Dr. Johnstone on an exciting

Congrats to Kamran Ahmed & team on this important brain mets screening study! The cumulative incidence of brain mets among pts with HR+/HER2-ve mbc whose dz progressed on 1st line ET was quite high (23% @ 6 mo) & comparable to that of pts with HER2+ (24%) and triple neg mbc (25%).

I have been saying this for years! After 1L progression in the metastatic setting we need routine MRI brain surveillance at least at every progression!

Finally brain MRI screening data in MBC. 25% at 6m is striking and higher than other reported studies of brain mets where symptoms led to imaging. Seems like common sense that early detection leads to less WBRT, smaller RT fields, less morbidity. Would be nice to see that too.

Great collaborative trial lead by Moffitt and OSU. FSRT, dual IO and avastin for recurrent GBM. Check it out at Editor - Neuro-Oncology Advances academic.oup.com/noa/advance-ar…

Congrats to Rituraj Upadhyay, MD and Joshua D. Palmer, MD on this important work! It’s great to have an additional, well tolerated option for these patients 🙌

Congrats Katarzyna Jerzak, our Sunnybrook Health Sciences Centre breast cancer medical oncolgist, continues to interrogate associations and novel therapeutics for her2+ve disease. Check out the latest paper as we continue to learn about her2 low status and brain metastases. pubmed.ncbi.nlm.nih.gov/40048670/

🙋‍♀️ vote for brain MRI as SOC at baseline & routine surv, esp for ⬆️ risk subtypes. If SOC for asymptomatic BCBM early, tx w/ targeted rads + right systemic tx, may ⬇️ freq/need for WBR - & ⬇️assoc deficits. ❓could this also lead to ⬇️LMD disease in high risk patients❓ #bcsm

Congratulations to the new members of our #RadOnc family here at Moffitt Cancer Center 🫶🏽🔥

A fantastic young woman with breast cancer leptomeningeal disease (LMD) we treated  on two first “in the world” trials using Moffitt science; working towards a cure for LMD (Clinical trial numbers NCT05809752 & NCT04588545).  moffitt.org/taking-care-of…

#J_Immunother_Cancer IF:10.3 Non-randomized phase Ib trial (n=12) showed nivolumab + stereotactic radiosurgery for metastatic breast cancer brain metastases had 94% 12-month local control, median OS 24.7mo, with no radionecrosis cases. PMID:40295143 pubmed.ncbi.nlm.nih.gov/40295143/

Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial. | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Fantastic work and collaboration, congrats Kamran Ahmed! MoffittRadOnc Moffitt Cancer Center

🚨Update Randomized Trial: Significantly Better KPS & Cognitive Function with SRS compared to HA-WBRT for 5-20 brain mets 🚨🚨🚨